Cellect Announces Successful First Cancer Patient Stem Cell Transplant

Cellect’s technology, ApoGraft™, aims to become a game changer in stem cells transplantations for cancer treatments
Company gets green light from DSMB Board for enrolling additional 2 cancer patients for ApoGraft™ transplantation treatments  
 
TEL AVIV, Israel, March 27, 2017  -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cell selection technology, announced today that the first stem cell transplant procedure has been successfully performed using its ApoGraft™ technology in the Company’s Phase I/II clinical trial in a blood cancer patient.  
 
Up to 50 percent of stem cell transplant procedures, such as bone marrow transplants, result in life-threatening rejection disease, known as Graft-versus-Host-Disease (GvHD). Cellect’s ApoGraft™ technology is aiming to turn stem cell transplants into a simple, safe and cost effective process, reducing the associated severe side effects, such as rejection and many other risks.
Read more: Cellect Biotechnology ( APOP )

Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia

HOUSTON, TX--( March 22, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced its lead candidate, Annamycin (also known as "Liposomal Annamycin"), an anthracycline, has received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).
 
Moleculin's Chairman and CEO, Walter Klemp, commented, "We are pleased to report this key milestone and the FDA's decision to grant Annamycin orphan drug designation. We look forward to announcing additional milestones in regard to our clinical pathway as we make further progress."
Read more: Moleculin Biotech Inc ( MBRX )

Update on Full Six-Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful Recovery of Function by Six Months Following AST-OPC1 Treatment

-Newly reported data on sixth and final patient in cohort further confirms previously announced improvements in hand and arm function following dosing-
 
FREMONT, Calif., March 21, 2017 -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, reported that including the sixth and final patient in the AIS-A 10 million cell cohort in the company's ongoing SCiStar Phase 1/2a clinical trial has further confirmed previously-announced motor function improvements at 6-months following administration of AST-OPC1. 
Read more: Asterias Biotherapeutics ( AST )

Pulmatrix Receives European Patent for its Inhaled Drug Delivery Technology

The patent extends Pulmatrix's broad protection for its innovative technology to Europe
 
LEXINGTON, Mass., March 21, 2017 -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received a key patent from the European Union.
 
"This new patent shows our continued ability to obtain patents that protect our unique iSPERSE inhaled drug technology—and that also reflect the advances we are making in drug delivery," said Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix. "It gives us a strong intellectual property protection position in Europe as we move forward with our drug candidates for COPD, fungal infections, and other diseases."
Read more: Pulmatrix Inc ( PULM )

IBEX earns $422,686 in fiscal Q2

Mr. Paul Baehr reports
 
IBEX REPORTS RESULTS FOR THE SECOND QUARTER AND THE SIX MONTHS ENDED JANUARY 31, 2017
 
IBEX Technologies Inc. has released its financial results for the six months ended Jan. 31, 2017.
 
"The second quarter of fiscal 2017 was a very positive quarter for the company with sales increasing 35 per cent over year ago and 27 per cent over the previous quarter," said Paul Baehr, IBEX president and chief executive officer. "Net earnings increased 114 per cent over the same quarter year ago and by 113 per cent over the previous quarter. In addition, cash and cash equivalents have increased by 8 per cent during the quarter despite the investment in our new fermentation facility.
Read more: Ibex Technologies Inc ( IBT )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker